Home > Boards > US Listed > Biotechs > Cel-Sci (CVM)

Yep.Not only that, but I kinda like the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
lightrock Member Profile
 
Followed By 20
Posts 3,215
Boards Moderated 0
Alias Born 10/15/16
160x600 placeholder
CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis Business Wire - 9/18/2020 9:00:00 AM
CEL-SCI Corporation Issues Letter to Shareholders Business Wire - 9/15/2020 9:15:00 AM
CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference Business Wire - 9/11/2020 9:00:00 AM
CEL-SCI Corporation Reports Third Quarter Fiscal 2020 Financial Results Business Wire - 8/11/2020 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 5:27:09 PM
CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment Business Wire - 7/24/2020 8:30:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 7/13/2020 6:03:54 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 7/2/2020 5:39:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 10:37:54 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 10:36:13 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 10:34:55 AM
CEL-SCI Corporation Receives $10 Million Through Warrant Exercises Business Wire - 6/30/2020 8:30:00 AM
CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series Business Wire - 6/24/2020 10:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 5/26/2020 5:24:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2020 5:23:10 PM
CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial Results Business Wire - 5/11/2020 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2020 5:04:18 PM
CEL-SCI’s Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine in Treatment of He... Business Wire - 5/4/2020 7:15:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 4/24/2020 5:50:15 PM
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head & Neck Cancer St... Business Wire - 4/23/2020 9:15:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/21/2020 6:01:11 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 5:06:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 5:03:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 4:59:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 4:56:22 PM
lightrock   Sunday, 09/22/19 10:21:39 PM
Re: Biobonic post# 25466
Post # of 33522 
Yep.

Not only that, but I kinda like the idea of not allowing a buyout, but
holding firm and continuing, growth, expansion, killing more cancers.

The big science thought for me, we have not even started much
drug combination studies.

That means, technically as well as business-wise, there would be
plenty of opportunity to partner and be the rising tide that
floats all boats.

If we get bought out by one major pharma, they might want to
keep it all for themselves and miss out on a greater wildfire.

I keep saying $45B is easy... depending how this goes...

Who needs a buyout ? Why short-change ourselves as well
as possibly the science...

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences